Description: Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. It is developing IMX-110 that is in Phase Ib/IIa clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. The company has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase Ib clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc. was incorporated in 2012 and is based in Los Angeles, California.
Home Page: www.immixbio.com
IMMX Technical Analysis
11400 West Olympic Boulevard
Los Angeles,
CA
90064
United States
Phone:
310 651 8041
Officers
| Name | Title |
|---|---|
| Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. | Co-Founder, Chairman & CEO |
| Mr. Gabriel Morris B.A. | CFO & Director |
| Mr. Sean Senn J.D., M.B.A., M.Sc., MBA, MSc | Co-Founder |
| Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D. | Scientific Co-Founder |
| Mr. Ben H. Lyon J.D. | Exec. VP & Gen. Counsel |
| Dr. Graham Ross FFPM, M.D. | Acting Chief Medical Officer & Head of Clinical Devel. |
| Mr. Nandan Oza B.S. | Head of Chemistry, Manufacturing & Control |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.1558 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-12-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 2 |